Phase 2
18 Years
70 Years
18 Years
70 Years
Open (Enrolling)
Both
Glioblastoma Multiforme
Both
Glioblastoma Multiforme
Trial Information
Inclusion Criteria:
- adult patients, 18-70 years of age;
- glioblastoma, confirmed histologically;
- no previous chemotherapy or radiotherapy for glioblastoma;
- non-methylated MGMT promoter in the tumor.
Exclusion Criteria:
- prior systemic treatment for glioblastoma multiforme;
- prior treatment with Avastin;
- significant cardiovascular disease;
- other active malignant disease.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Progression-free survival
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: Paul-Ehrlich-Institut
Study ID:
ML21965
NCT ID:
NCT00967330
Start Date:
June 2010
Completion Date:
December 2014
Related Keywords:
- Glioblastoma Multiforme
- Glioblastoma
Name | Location |
|---|
